Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Is Amgen's FOURIER Enough For Physicians, Payers To Expand Repatha Use?

Executive Summary

Detailed results presented at ACC show a reduction in risk of major adverse cardiovascular events, but perhaps not at the level hoped for by payers.

Advertisement

Related Content

Amgen Hit By Enbrel 'Peculiarities' And Repatha Resistance
Can Cholesterol Drug Sponsors Make The Case For Statin Intolerance?
Quick Commercial Standouts Lacking Among 2016 US Launches
Esperion Says FDA On Board With Filing Strategy For Bempedoic Acid
What To Look Out For At ACC
Pfizer’s Bococizumab Discontinuation Increases Uncertainty For Other PCSK9s
PCSK9 Inhibitors' First Birthday Brings Sluggish Sales And More Bad Press

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC098413

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel